The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic factors for 90-day mortality in patients with solid malignancies treated on Phase 1 trials sponsored by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute.
 
Kit Man Wong
No Relationships to Disclose
 
Larry Rubinstein
No Relationships to Disclose
 
Matthew Rinker
No Relationships to Disclose
 
Gary Lee Smith
No Relationships to Disclose
 
Elad Sharon
No Relationships to Disclose
 
S. Gail Eckhardt
Stock and Other Ownership Interests - Entremed
Honoraria - Boehringer Ingelheim; Janssen Oncology; Kyowa Hakko Kirin; Lilly/ImClone
Consulting or Advisory Role - CASI Pharmaceuticals; OnKure; Pfizer; Sanofi; Suvica; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); cleave biosciences (Inst); Genentech (Inst); OncoMed (Inst); Rexahn Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Genentech; Kyowa Hakko Kirin; Lilly/ImClone; Sanofi
 
Wells A. Messersmith
Consulting or Advisory Role - Immunomedics; OncoMed
Research Funding - GlaxoSmithKline; Immunomedics; Millennium; OncoMed; Pfizer; Roche/Genentech
 
Stephen Leong
Stock and Other Ownership Interests - Amarin Corporation; Antares Pharmaceuticals; ARIAD; Spectrum Pharmaceuticals
Consulting or Advisory Role - Ipsen; New B Innovation
Research Funding - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Pamela Jo Harris
No Relationships to Disclose
 
Dexiang Gao
No Relationships to Disclose